A new synthetic matrix metalloproteinase inhibitor modulates both angiogenesis and urokinase type plasminogen activator activity

Angiogenesis

Volumn 2, Issue 4, 1998, Pages 319-329

  Shono, Tadahisa ^a,b   Motoyama, Masaaki ^c   Tatsumi, Kunihiko ^c   Ulbrich, Norbert ^d   Iwamoto, Yukihide ^a   Kuwano, Michihiko ^a   Ono, Mayumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis; BB 2516; BB 94; Matrix metalloproteinase; OPB 3206; Plasminogen activator

Indexed keywords

BOVINAE;

EID: 0004025148     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009207820233     Document Type: Article

References (39)

1. Flokman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1 (1), 27-31.
2. Karp JE, Broader S. Molecular foundation of cancer: New targets for intervention. Nature Med 1995 (4), 1, 309-320.
3. Hanahan D. Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86 (3), 353-364.
4. Kim KJ, Li, B, Winer, J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362 (6423), 841-844.
5. Kondo S, Asano M, Suzuki S. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993; 194 (3), 1234-1241.
6. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367 (6463), 576-579.
7. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264 (5158), 569-571.
8. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathways by distinct αv integrins. Science 1995; 270 (5241), 1500-1502.
9. O' Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79 (2), 315-328.
10. O' Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996; 2(6), 689-692.
11. O' Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88 (2), 277-285.
12. Sidky YA, Borden E. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular respones. Cancer Res 1994; 47 (19), 5155-5161.
13. Johnson MD, Kim HC, Chesler L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994; 160 (1), 194-202.
14. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. New Engl J Med 1992; 326 (22), 1456-1463.
15. Fisher C, Gilbertson-Beadling S, Powers EA, et al. Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 1994; 162 (2), 499-510.
16. Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst. 1995; 87 (4), 293-298.
17. Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for loner-term studies. Clin Cancer Res 1998; 4 (5); pp. 1101-1109.
18. Sato Y, Morimoto A, Kiue A, et al. Irsogladine is a potent inhibitor of angiogenesis. FEBS Lett 1993; 322 (2), 155-158.
19. Ushiro S, Ono M, Nakayama J, et al. New norterpenoid isolated from anti-rheumatoid arthritic plant, tripterygium wilfordii, modulates tumor growth and neovascularization. Int J Cancer 1997; 72 (4), 657-663.
20. Ono M, Kawahara, N, Goto D, et al. Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, Irsogladine. Cancer Res 1996; 56 (7), 1512-1516.
21. Davis B, Brown PD, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53 (9), 2087-2091.
22. Chirivi RGS, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58 (3), 460-464.
23. Wang X, Fu X, Brown PD, et al. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54 (17), 4726-4728.
24. Eccles SA, Box GM, Court WJ, et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56 (12), 2815-2822.
25. Watson SA. Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55 (16), 3629-3633.
26. Sato H, Takino, T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370 (6484), 61-65.
27. Thorgeirsson UP, Yoshiji H, Sinha CC, Gomez DE. Breast cancer; tumor neovasculature and the effect of tissue inhibitor of metalloproteinases-1 (TIMP-1) on angiogenesis. In Vivo 1996;10 (2), 137-144.
28. Maciag T, Weibel MK, Pye EK Urokinase. Methods Enzymol 1974; 34B, 451-459.
29. Yang H, Henkin J Competitive inhibitors of human urokinase. Fibrinolysis 1992; 6 (1), 31-34.
30. Sato Y, Rifkin DB. Autocrine activities of baic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988; 107 (3), 1199-1205.
31. Sato Y, Okamura K, Morimoto A, et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 1993; 204 (2), 223-229.
32. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79 (2), 185-188.
33. Gately S, Twardowski P, Stack MS, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996; 56 (21), 4887-4890.
34. Gimbrone MA, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974; 52 (2), 413-419.
35. Ito Y, Iwamoto Y, Oshima N, Sugioka Y. Quantitative evaluation of the effects of an angiogenesis inhibitor, TNP-470, by an in-vivo tumour angiogenesis assay using basement membrane extracts. Cancer J 1996; 9 (2), 95-100.
36. Abe T, Okamura K, Ono M, et al. Induction of vascular endothelial tubular morphogenesis by human glioma cells. J Clin Invest 1993; 92 (1), 54-61.
37. Jimi S, Ito K, Kohno K, et al. Modulation of bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem Biophys Res Commun 1995; 211 (2), 476-483.
38. Shono T, Ono M, Izumi H, et al. Involvement of the transcription factor NF-κB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 1996; 16 (8), 4231-4239.
39. Ito K, Ryuto M, Ushiro S, et al. Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on matrigel. J Cell Physiol 1995; 162 (2), 213-224.